Metelimumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Metelimumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target TGF beta 1
Clinical data
Legal status Investigational
Identifiers
CAS number 272780-74-2 N
ATC code None
Chemical data
Formula ?
 N (what is this?)  (verify)

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. Touted as a drug of the future,[1] metelimumab was dropped from further development in favour of fresolimumab,[2] which is currently being developed by Genzyme.[3]

History[edit]

Metelimumab was isolated by Cambridge Antibody Technology (CAT) using its phage display technology. In 2000, CAT signed a collaborative deal with Genzyme to further develop TGF beta antibodies.[4][5]

In 2004, CAT and Genzyme revealed that Phase I/II trials of metelimumab for scleroderma showed this antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.[6]

Initial trials targeted the skin condition scleroderma[7] but, after some unsuccessful clinical trial results, the product was dropped in favour of fresolimumab,[2] which is currently being developed by Genzyme.[3]

References[edit]

  1. ^ http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=860002&p_IsPs=N
  2. ^ a b http://www.independent.co.uk/news/business/news/cat-may-abandon-skin-drug-after-trial-results-disappoint-569445.html
  3. ^ a b http://www.genzymeoncology.com/onc/research/onc_p_research.asp
  4. ^ http://prnwire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-28-2000/0001324438&EDATE=
  5. ^ http://www.drugdiscoveryonline.com/article.mvc/Cambridge-Antibody-Genzyme-to-collaborate-on-0001?VNETCOOKIE=NO
  6. ^ http://goliath.ecnext.com/coms2/gi_0199-693661/CAT-192-is-safe-but.html
  7. ^ http://www.genzymeoncology.com/onc/clinical/trialdetailresults.asp?nct=NCT00043706